Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874176 | 1.00 | HTT (0.55) | HTTHPGDCA12CA1CA2 | |
| SCHEMBL20188098 | 0.87 | HPGD (0.65) | HTTHPGDCA12CA1CA2 | |
| SCHEMBL22015905 | 0.87 | HPGD (0.65) | HTTHPGDCA12CA1CA2 | |
| SCHEMBL21499221 | 0.86 | ALDH1A1 (0.57) | HTTHPGDCA12CA1CA2 | |
| SCHEMBL20187714 | 0.83 | HPGD (0.59) | HTTHPGDCA12CA1CA2 | |
| SCHEMBL18470911 | 0.83 | GPR119 (0.43) | HTTCA12CA1CA2CA9 | |
| SCHEMBL17801101 | 0.81 | USP2 (0.54) | HPGDMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL5324137 | 0.81 | CYP2C9 (0.62) | HTTHPGDCA12CA1CA2 | |
| SCHEMBL3067260 | 0.81 | ALDH1A1 (0.58) | HTTHPGDCA12CA1CA2 | |
| SCHEMBL3898465 | 0.81 | HPGD (0.61) | HTTHPGDCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269814-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2025-04-08 | — | — | US | disclosed |
| CN-112375073-B | Antifungal compounds | 普尔莫赛德有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20230295133-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL TO TREAT MYCOSES | PULMOCIDE LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| US-20230295133-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL TO TREAT MYCOSES | PULMOCIDE LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| US-11661415-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11661415-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11661415-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-20210238169-A1 | PROCESS FOR PREPARING A COMPOUND OF FORMULA (XIII) | PULMOCIDE LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20210238169-A1 | PROCESS FOR PREPARING A COMPOUND OF FORMULA (XIII) | PULMOCIDE LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-11008307-B2 | Compounds which are used in the preparation of the compound of formula (I) | PULMOCIDE LIMITED (GB) | 2021-05-18 | — | — | US | disclosed |
| US-20170320858-A1 | COMPOUND | PULMOCIDE LIMITED (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-3227277-A1 | ANTIMYCOTIC COMPOUND | Pulmocide Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| EP-3227278-A1 | ANTIMYCOTIC COMPOUND | Pulmocide Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-20170037035-A1 | COMPOUND | PULMOCIDE LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| US-20170037035-A1 | COMPOUND | PULMOCIDE LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| US-20170037035-A1 | COMPOUND | PULMOCIDE LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| WO-2016087880-A1 | ANTIMYCOTIC COMPOUND | PULMOCIDE LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087878-A1 | ANTIMYCOTIC COMPOUND | PULMOCIDE LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087878-A1 | ANTIMYCOTIC COMPOUND | PULMOCIDE LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087880-A1 | ANTIMYCOTIC COMPOUND | PULMOCIDE LIMITED (GB) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320858-A1 | COMPOUND | MYC, DPM1, ERG28 | HTT 3926/4885HPGD 2721/4885CA12 311/4885 |
| US-11008307-B2 | Compounds which are used in the preparation of the compound of formula (I) | CYP11B2, CYP11B1, CYP21A2 | HTT 2633/4885HPGD 246/4885CA12 221/4885 |
| US-11661415-B2 | Process for preparing a compound useful to treat mycoses | DPM1, CYP51A1, ERG28 | HTT 4807/4885HPGD 929/4885CA12 632/4885 |
| US-20230295133-A1 | PROCESS FOR PREPARING A COMPOUND USEFUL TO TREAT MYCOSES | DPM1, CYP51A1, ERG28 | HTT 4807/4885HPGD 929/4885CA12 632/4885 |
| US-20210238169-A1 | PROCESS FOR PREPARING A COMPOUND OF FORMULA (XIII) | CYP2F1, CYP4A11, CYP4F11 | HTT 4447/4885HPGD 614/4885CA12 381/4885 |
| US-20170037035-A1 | COMPOUND | DPM1, MYC, ERG28 | HTT 4232/4885HPGD 2710/4885CA12 287/4885 |
| US-12269814-B2 | Process for preparing a compound useful to treat mycoses | C1R, CBR1, CBR3 | HTT 1887/4885HPGD 1735/4885CA12 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.